Retinopathy Of Prematurity Clinical Trials 2023

Retinopathy Of Prematurity Clinical Trials 2023

Retinopathy Of Prematurity research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in retinopathy of prematurity clinical trials today.

Retinopathy Of Prematurity Clinical Trials

Here are the 0 most popular medical studies for retinopathy of prematurity

Popular filter options for retinopathy of prematurity trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to retinopathy of prematurity

What are the top hospitals conducting retinopathy of prematurity research?

In the realm of innovative clinical trials for retinopathy of prematurity, several leading hospitals are making significant strides. Duke University Eye Center in Durham, North carolina, is at the forefront with four ongoing trials dedicated to this condition and a total of six completed studies. The center initiated its first retinopathy of prematurity trial back in 2001, showcasing their long-standing commitment to advancing knowledge in this field. On the East Coast, Boston Children's Hospital has been actively involved as well, currently undertaking three trials for retinopathy of prematurity and having completed a commendable four studies thus far. Their contributions began more recently, with their inaugural trial recorded in 2015.

Moving further inland to Indianapolis, Indiana University School of Medicine is also playing an essential role in researching retinopathy of prematurity. They currently have two active trials underway and have conducted two previous investigations into this condition since recording their first trial just last year in 2022. Similarly contributing from Little Rock, Arkansas Children's Hospital and the University of Arkansas Medical Sciences are conducting two active retinopathy of prematurity trials while boasting two groundbreaking past studies under their belt since entering into the field during the same year.

Finally yet importantly adding itself to this list is the Gavin Herbert Eye Institute at the University of California Irvine; they too possess impressive records performing research on infants born prematurely by participating actively being partakers within current testing protocols toward seeking any improvement over diseases affecting premature babies eyesight such as Retnophaty Of Prematureity (ROP). Currently handling up-to-date procedures relevant towards ROP involving not one but rather Two different tests that focus exclusively upon studying these cases- all whilst reflecting similar patterns witnessed elsewhere: It comes relatively late joining ROP-relevant research which it only started engaging within scientific experimentation & investigation a few short months ago marking 2022 as its very own "initiation" phase

These esteemed institutions represent beacons of hope for those affected by retinopathy of prematurity, shedding light on potential breakthroughs and improved treatments. With their dedication to ongoing research and clinical trials, they pave the way towards a brighter future for premature infants worldwide.

Which are the best cities for retinopathy of prematurity clinical trials?

When it comes to retinopathy of prematurity clinical trials, several cities have emerged as leading centers for research. Houston, Texas takes the lead with 8 active trials focusing on treatments like Bevacizumab specifically for ROP. Chicago, Illinois follows closely behind with 6 ongoing studies exploring potential interventions such as OHB-607. Indianapolis and Boston tie at 5 active trials each, investigating the effectiveness of Bevacizumab and other treatment options. Lastly, Durham, North carolina conducts 4 active studies utilizing techniques like retinal photographs to advance our understanding and management of this condition. These cities serve as hubs for cutting-edge research in retinopathy of prematurity and offer hope for improved outcomes in affected infants.

Which are the top treatments for retinopathy of prematurity being explored in clinical trials?

Retinopathy of prematurity, a condition affecting premature infants' vision, is the focus of ongoing clinical trials exploring potential treatments. Leading the way in these efforts is bevacizumab, currently being tested in two active trials for retinopathy of prematurity. Since its initial listing in 2008, it has been involved in a total of six trials dedicated to this specific condition. Additionally, researchers are investigating the efficacy of retinal photographs as a treatment option through one active trial - an innovative approach introduced just last year. Another promising avenue under investigation is OHB-607 with one active trial and first listed in 2019's all-time tally for retinopathy of prematurity studies. As these clinical trials progress, we hope to discover groundbreaking interventions that will improve the outcomes for vulnerable premature infants affected by this sight-threatening condition.

What are the most recent clinical trials for retinopathy of prematurity?

Recent clinical trials for retinopathy of prematurity have shown promising developments in the field. Bevacizumab, a medication that inhibits blood vessel growth, has been tested in both Phase 2 and Phase 3 trials for treating this condition. The results have indicated its potential effectiveness as a treatment option. Another experimental drug called OHB-607 has also undergone Phase 2 testing specifically for retinopathy of prematurity. These advancements bring hope to preterm infants at risk of developing this eye disorder, offering new possibilities for improved outcomes in their visual health.

What retinopathy of prematurity clinical trials were recently completed?

In the realm of retinopathy of prematurity, a recent milestone was reached with the completion of an important clinical trial. Sponsored by Regeneron Pharmaceuticals, this trial investigated the potential benefits of aflibercept in treating this condition. The study concluded in October 2019, shedding light on new possibilities for managing and mitigating retinopathy of prematurity.